Skip to main content

Advertisement

SpringerLink
Log in

Acute HCV Treatment: What Should We Do in the DAA Era?

  • Hepatitis C (H Vargas and S Flamm, Section Editors)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Acute hepatitis C infection is a growing concern in the USA, especially in light of the opioid epidemic. Prior treatment data consisted of trials in patients receiving interferon-based regimens. There is now emerging evidence regarding the safety and efficacy of direct-acting antivirals for the treatment of acute hepatitis C. This review summarizes the current evidence on the treatment of acute HCV in the DAA era.

Recent Findings

Certain populations, such as people who inject drugs, or HIV-positive men who have sex with men, may benefit from early treatment of acute HCV. As compared with chronic hepatitis C, shorter durations of treatment appear highly effective in acute infection, resulting in reduced viral transmission, as well as potentially reduced overall costs of care related to this disease.

Summary

Further studies are needed to clarify the optimal drug combinations and treatment durations to achieve sustained virologic response in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–40. https://doi.org/10.3748/wjg.v22.i34.7824.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42. https://doi.org/10.1002/hep.26141.

    Article  PubMed  Google Scholar 

  3. The Elimination of Hepatitis C. In: Buckley, GJ and Strom BL, editors. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. 2016. National Academies Press: Washington, DC.

  4. Centers for Disease Control and Prevention. Hepatitis C questions and answers for health professionals. 2018. https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#section1. Accessed 12/1/2018

  5. Surveillance for viral hepatitis – United States, 2016. https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm. Accessed 12/8/2018.

  6. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59(10):1411–9. https://doi.org/10.1093/cid/ciu643.

    Article  CAS  PubMed  Google Scholar 

  7. Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged </=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453–8.

    PubMed  PubMed Central  Google Scholar 

  8. Hajarizadeh B, Grebely J, Dore GJ. Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol. 2012;57(6):1349–60. https://doi.org/10.1016/j.jhep.2012.07.007.

    Article  PubMed  Google Scholar 

  9. Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Muir D, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS. 2009;23(1):89–93. https://doi.org/10.1097/QAD.0b013e32831940a3.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26(4):401–12. https://doi.org/10.1016/j.bpg.2012.09.009.

    Article  PubMed  Google Scholar 

  11. Thomson EC, Fleming VM, Main J, Klenerman P, Weber J, Eliahoo J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2011;60(6):837–45. https://doi.org/10.1136/gut.2010.217166.

    Article  PubMed  Google Scholar 

  12. • Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34–41. https://doi.org/10.1111/j.1365-2893.2005.00651.x A landmark systematic review that provides the estimates for spontaneous clearance of acute HCV and factors associated with clearance.

    Article  CAS  PubMed  Google Scholar 

  13. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59(1):109–20. https://doi.org/10.1002/hep.26639.

    Article  CAS  PubMed  Google Scholar 

  14. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008;198(9):1337–44. https://doi.org/10.1086/592171.

    Article  PubMed  Google Scholar 

  15. Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, et al. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J Hepatol. 2013;59(2):221–8. https://doi.org/10.1016/j.jhep.2013.04.007.

    Article  PubMed  Google Scholar 

  16. Beinhardt S, Payer BA, Datz C, Strasser M, Maieron A, Dorn L, et al. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol. 2013;59(5):972–7. https://doi.org/10.1016/j.jhep.2013.06.028.

    Article  PubMed  Google Scholar 

  17. Deterding K, Gruner N, Buggisch P, Wiegand J, Galle PR, Spengler U, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis. 2013;13(6):497–506. https://doi.org/10.1016/s1473-3099(13)70059-8.

    Article  PubMed  Google Scholar 

  18. Doyle JS, Deterding K, Grebely J, Wedemeyer H, Sacks-Davis R, Spelman T, et al. Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat. 2015;22(12):1020–32. https://doi.org/10.1111/jvh.12429.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. •• Bethea ED, Chen Q, Hur C, Chung RT, Chhatwal J. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. Hepatology. 2018;67(3):837–46. https://doi.org/10.1002/hep.29611 A study that developed a microsimulation model that showed treating acute HCV is cost-effective, and in some cases, cost-saving compared with deferred treatment.

    Article  PubMed  PubMed Central  Google Scholar 

  20. AASLD/IDSA. Management of Acute HCV Infection. 2017. https://www.hcvguidelines.org/unique-populations/acute-infection. Accessed 12/8/2018 2018.

  21. Kanzaki H, Takaki A, Yagi T, Ikeda F, Yasunaka T, Koike K, et al. A case of fulminant liver failure associated with hepatitis C virus. Clin J Gastroenterol. 2014;7(2):170–4. https://doi.org/10.1007/s12328-014-0454-x.

    Article  PubMed  Google Scholar 

  22. Tracy B, Shrestha R, Stein L, Bhasin D, Pollinger H, Rubin RA. Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure. Transpl Infect Dis. 2017;19(3). https://doi.org/10.1111/tid.12690.

  23. Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17(11):2790–802. https://doi.org/10.1111/ajt.14381.

    Article  CAS  PubMed  Google Scholar 

  24. EASL. Recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511. https://doi.org/10.1016/j.jhep.2018.03.026.

    Article  Google Scholar 

  25. Basu PP, Shah NJ, Aloysius MM, Brown RS Jr, editors. Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir for acute hepatitis C: a RCT: SLAM C study. 25th Annual Conference of APASL. Tokyo: Hepatology International; 2016.

    Google Scholar 

  26. •• Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis. 2017;17(2):215–22. https://doi.org/10.1016/s1473-3099(16)30408-x A trial showing 100% SVR rate for 6 weeks of ledipasvir/sofosbuvir in genotype 1 acute HCV.

    Article  CAS  PubMed  Google Scholar 

  27. • Rockstroh JK, Bhagani S, Hyland RH, Yun C, Dvory-Sobol H, Zheng W, et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2017;2(5):347–53. https://doi.org/10.1016/s2468-1253(17)30003-1 A trial of ledipasvir/sofosbuvir for 6 weeks in patients with genotype 1 or 4 acute HCV coinfected with HIV; sub-optimal SVR rate seen in those with elevated baseline viral load.

    Article  PubMed  Google Scholar 

  28. •• Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, et al. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. J Viral Hepat. 2018;25(10):1180–8. https://doi.org/10.1111/jvh.12917 A trial that demonstrated a 97% SVR rate with 8 weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir (with ribavirin) in patients with recent HCV genotype 1 infection.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Liver Disease and Transplantation, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY, USA

    Zurabi Lominadze & Robert S. Brown Jr

  2. Division of Gastroenterology and Hepatology, Weill Cornell Medical College, 1305 York Avenue, 4th Floor, New York, NY, 10021, USA

    Robert S. Brown Jr

Authors
  1. Zurabi Lominadze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert S. Brown Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert S. Brown Jr.

Ethics declarations

Conflict of Interest

Robert S. Brown, Jr., reports grants and personal fees from Gilead, grants and personal fees from Abbvie, grants and personal fees from Merck, and grants and personal fees from BMS, outside the submitted work. Zurabi Lominadze declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Hepatitis C

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lominadze, Z., Brown, R.S. Acute HCV Treatment: What Should We Do in the DAA Era?. Curr Hepatology Rep 18, 216–221 (2019). https://doi.org/10.1007/s11901-019-00463-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-019-00463-3

Keywords

Search

Navigation